Lebrikizumab: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
CIPM (Spain), DMC (Denmark) and HAS (France), among others, recommended or restricted lebrikizumab, while AOTMIT (Poland) and NYE METODER (Norway) did not recommend it.
The record spans 2.4 years, opening at DMC (Denmark) on 1 Feb 2024 and running to 2026.
No assessment is on file from PHARMAC (New Zealand), which is among the eight highest-volume agencies here.
Not every gap is a refusal: for lebrikizumab, 1 was withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The file is active: 15 of 15 records date from 2023 or later.
4 distinct indication wordings are recorded for lebrikizumab by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
2 of these 15 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
DMC (Denmark) was first to assess lebrikizumab, on 1 Feb 2024; AOTMIT (Poland) did not open a file until 26 Feb 2025 — a moderate spread of 1 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 11 of 15 dated records fall in 2024 alone.
Restriction is doing real work here: 4 of 12 decisive outcomes narrowed lebrikizumab to a subgroup rather than accepting or refusing it outright, at HIRA (South Korea), NICE (England) and SMC (Scotland) among others.
2 of the 13 agencies here assessed lebrikizumab more than once, PBAC (Australia) most often at 2 entries — repeat review is the norm for this molecule rather than the exception.
lebrikizumab has been through 13 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for lebrikizumab reads 6 recommended, 4 restricted, 2 not recommended and 1 withdrawn, with 2 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| AOTMIT (Poland) | 26 Feb 2025 | programu lekowego „Leczenie chorych z atopowym zapaleniem skóry (ICD-10: L20) | not recommended | source |
| HIRA (South Korea) | 6 Feb 2025 | 아토피 피부염 | reimbursable only at the evaluated price | source |
| TLV (Sweden) | 24 Jan 2025 | Ebglyss ingår i högkostnadsskyddet med begränsning | restricted subsidy | source |
| SMC (Scotland) | 11 Nov 2024 | Treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older with a body weight of at least 40 kg who are candidates for systemic therap… | accepted (restricted) | source |
| ZIN (Netherlands) | 12 Sep 2024 | Advies - vergoed lebrikizumab (Ebglyss®) voor de behandeling van matig tot ernstig eczeem | reimbursed (sluis) | source |
10 further decisions for lebrikizumab, across 8 agencies, are not shown here. They include the most recent record on file, 2026 from PBAC (Australia); its outcome is in the subscriber dataset. They link to 8 further source documents.
Related molecules
- dupilumab — same ATC class D11A — Other dermatologicals
- abrocitinib — same ATC class D11A — Other dermatologicals
- nemolizumab — same ATC class D11A — Other dermatologicals
- delgocitinib — same ATC class D11A — Other dermatologicals
- diclofenac — same ATC class D11A — Other dermatologicals
- ivermectin — same ATC class D11A — Other dermatologicals
Coverage: 15 decisions for lebrikizumab from 13 agencies, 2024 to 2026. Data to 7 Sep 2026. ATC class D11A — Other dermatologicals. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.